You are here

First Generic of HIV-1 Antiretroviral Atazanavir Launches in the U.S.

Brand-name Reyataz (Bristol-Myers Squibb) generated annual sales of more than $400 million in 2017

Teva Pharmaceutical Industries Ltd. has launched the first generic version of Reyataz (atazanavir, Bristol-Myers Squibb) capsules in the U.S. Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection for patients 6 years of age and older weighing at least 15 kg.

Reyataz® had annual sales of approximately $402 million in the U.S., according to IMS data as of October 2017.

Source: Teva; December 27, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs